Washington University School of Medicine
Advanced cervical cancer patients treated with standard of care (SOC) chemoradiation plus glutaminase inhibition with telaglenastat (CB-839) will have increased progression-free survival (PFS) compared to historical rates for patients receiving SOC chemoradiation alone.
Inclusion Criteria: Patients eligible for definitive chemoradiotherapy, including brachytherapy * Patient age ≥ 18 years. * Patients with histologically confirmed newly diagnosed advanced cervical cancer (squamous, adenosquamous, adenocarcinoma or poorly differentiated); Federation of Gynecology and Obstetrics (FIGO) 2018 clinical stages III-IVA. * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 * Absolute neutrophil count ≥ 1,500/mcL. * Platelets ≥ 100,000/mcL. * Hemoglobin ≥ 8 g/dL (can be transfused prior to study). * Total bilirubin ≤ 1.5 x institutional upper limit of n…
-800 mg twice per day by mouth
* Standard of care * External beam radiation therapy delivered daily 4 days a week and 1 day per week of brachytherapy.
* Standard of care * Weekly administration of cisplain
Arctuva estimate
Verify or correct the compensation shown for this listing.